IL-6 Shows Promise as Early Sepsis biomarker ⁣in High-Risk groups

A recent⁢ study suggests that interleukin-6 (IL-6) could be ⁤a ⁣valuable diagnostic tool for the early detection of sepsis, notably in vulnerable populations such as newborns, children, and pregnant women.The research, presented at the ⁤Global 2025 Escmid conference, marks the first comprehensive evaluation of IL-6’s diagnostic performance across all three of these high-risk groups.

Sepsis, a life-threatening condition arising from the body’s overwhelming⁣ response to an infection, remains a major global health ⁣challenge. The condition‍ is responsible for an estimated 11 million deaths each year.

Young children, especially those under the⁢ age of five, and pregnant women face a heightened risk of sepsis due to immunological changes‍ and increased susceptibility to infections.Diagnosing sepsis in pregnant women presents unique challenges,⁣ as normal physiological changes ⁣during pregnancy can obscure early warning signs of the disease.

The ⁣Need for Early Detection

Early and accurate diagnosis is critical for improving outcomes in sepsis cases. ⁤However, the non-specific nature of sepsis symptoms and ‍the limitations of traditional biomarkers, such as C-reactive protein (CRP) and procalcitonin (PCT), which exhibit delayed responses and suboptimal sensitivity, complicate early detection efforts.

Given the rapid progression of sepsis, medical professionals are actively seeking‍ biomarkers that can enable faster, more precise diagnoses and facilitate timely, effective treatment interventions.

Study Details

The retrospective study, published in the⁢ European Medical Journal – EMJ, analyzed blood samples ‍collected ⁢at regular intervals from 252 patients suspected of⁢ having sepsis. The ⁤study cohort included 111 pediatric patients,72 pregnant women,and 69 newborns.

Researchers classified patients based⁢ on the type of infection (bacterial, viral, ⁢or absence of infection) and their physiological response (normal, systemic inflammatory response syndrome, sepsis, or septic shock). Diagnostic accuracy was assessed using⁢ the area under the receiver operating characteristic (AUROC) curve, where a score of ⁣1.0 indicates a perfect test and 0.5 indicates a completely ineffective test.

IL-6 Performance

The study found that IL-6 consistently outperformed traditional biomarkers in differentiating bacterial infections from‍ non-bacterial infections.IL-6 achieved AUROC scores of 0.91 0.94 in pregnant patients, and 0.86 in newborns. The biomarker also proved effective in assessing sepsis severity, successfully distinguishing between mild infections, sepsis, and septic shock – a crucial capability for tailoring treatment strategies.

In⁤ terms of sensitivity and specificity, IL-6 exceeded 80% in pediatric and pregnant patients, detecting bacterial infections with a sensitivity of 91% in children and 94% ‍in pregnant women. While IL-6 maintained high specificity (97.1%) in newborns, ⁤its sensitivity was lower (67.6%).

the study authors ⁤suggest that the lower sensitivity and‍ AUROC values observed in newborns may be partially attributed to the inherent complexity⁣ of diagnosing neonatal sepsis, for which a universally accepted standard definition is lacking. The wide range of clinical manifestations associated with neonatal sepsis may ‍also contribute to these differences.

Advantages of IL-6

Dr. Seán ⁤Whelan, the lead author of the study, highlighted the advantages of IL-6 over traditional biomarkers. “The secretion of IL-6 increases in one to two hours, reaches a peak at six hours, and drops in 24 hours, while CRP and PCT reach⁢ their peaks⁣ much later, at⁤ 48 and 24 hours, respectively,”⁢ Dr. whelan said. “This offers a key advantage over existing markers for the early identification of sepsis.”

Dr. Whelan also noted the increasing clinical use of‍ IL-6 testing. “In ⁤our institutions – Round Hospital and Children’s Health Ireland – IL-6 is already used for these categories⁣ of patients,” he stated.

The increased adoption of IL-6 ⁢testing has been facilitated by the availability⁢ of commercial assays compatible with⁢ widely used laboratory platforms, providing ‍real-time results. The COVID-19 pandemic further accelerated this trend,⁤ with IL-6 testing becoming more common for evaluating inflammation ⁣in patients.

Dr. Whelan⁢ concluded that ‍the study results support⁣ the potential of IL-6 as an meaningful biomarker in the diagnosis of sepsis.

The authors believe that widespread use of IL-6,⁣ in conjunction with clinical evaluation, could substantially improve medical decision-making and the initiation of personalized treatments in high-risk patients.